Source comparison
MOTS-c Receptor Pharmacology: Type, Mechanism, Effect Comparison
MOTS-c Direct DHFR/MTHFD1L inhibition → AICAR accumulation → AMPK activation Folate metabolism, AMPK pathway, oxidative stress response Yes. Redox-sensitive nuclear entry under metabolic stress Phase I trials ongoing Metformin Complex I inhibition → AMP:ATP ra
This comparison does not assign a generated winner or score.
- MOTS-c
- Direct DHFR/MTHFD1L inhibition → AICAR accumulation → AMPK activation
- Folate metabolism, AMPK pathway, oxidative stress response
- Yes. Redox-sensitive nuclear entry under metabolic stress
- Phase I trials ongoing
- Metformin
- Complex I inhibition → AMP:ATP ratio elevation → AMPK activation
- Electron transport chain, hepatic gluconeogenesis
- No. Cytoplasmic mechanism only
- FDA-approved (T2DM)
- GLP-1 agonists
- GLP-1 receptor (GPCR) activation → cAMP signaling → insulin secretion
- Pancreatic beta cells, gastric emptying
- No. Surface receptor pathway
- FDA-approved (T2DM, obesity)
- Insulin
- Insulin receptor (RTK) activation → PI3K-AKT signaling
- Glucose uptake, glycogen synthesis, lipid storage
- No. Cytoplasmic signaling cascade
- FDA-approved (diabetes)
- AICAR (direct)
- Direct AMPK activation via AMP mimicry
- AMPK pathway (same downstream as MOTS-c)
- No. Remains cytoplasmic
- Research-grade only
- Bottom Line Assessment
- MOTS-c is the only peptide that combines AMPK activation with direct nuclear transcriptional regulation, offering both immediate metabolic effects and long-term adaptive reprogramming without requiring a cell-surface receptor